In Utero Exposure to SARS-CoV-2 (COVID-19) and Cardiovascular and Metabolic Endpoints in Early Life (PROSPER)
Study Overview
Status
Status
Conditions
Conditions
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Massachusetts General Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Mother with or without prenatal COVID-19 who was enrolled in the MGH COVID-19 Perinatal Biorepository and her child (9-24 months old)
Exclusion Criteria:
- Child with any history of documented COVID-19
- Mother who received the COVID-19 vaccine during pregnancy with her child
- Significant chronic illness in mother or child judged by the investigator to represent a contraindication to study participation
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
|---|
|
SARS-CoV-2 Exposed Dyads
Mothers who had SARS-CoV-2 during pregnancy and their offspring
|
|
SARS-CoV-2 Unexposed Dyads
Mothers who were not known to have SARS-CoV-2 during pregnancy and their offspring
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Aortic pulse-wave velocity
Time Frame: Baseline
|
Baseline
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Skinfold thicknesses (subscapular, triceps)
Time Frame: Baseline
|
Baseline
|
|
Weight-for-length z-score
Time Frame: Baseline
|
Baseline
|
|
Systolic and diastolic blood pressure
Time Frame: Baseline
|
Baseline
|
|
Beta index of aortic stiffness using echocardiogram
Time Frame: Baseline
|
Baseline
|
|
Aortic intima-media thickness using echocardiogram
Time Frame: Baseline
|
Baseline
|
|
Urinary angiotensin peptide levels
Time Frame: Baseline
|
Baseline
|
|
Urinary angiotensin converting enzyme (ACE) levels
Time Frame: Baseline
|
Baseline
|
|
Left ventricular mass
Time Frame: Baseline
|
Baseline
|
|
Left ventricular dimensions
Time Frame: Baseline
|
Baseline
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
Other Study ID Numbers
- 2021P001107
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.